Stephen B. Willingham

Author

Also Known As

Bergstralh, Daniel T., Brickey, Willie June, Chunyan Gu, Duncan, Joseph A., S B Willingham, S. Willingham, S.B. Willingham, Stephen B Willingham, Stephen B. Willingham, Stephen Willingham

Publications

9.3K

Citations

H-Index

Concepts

All Affiliations

Stanford University University of North Carolina at Chapel Hill California Institute for Regenerative Medicine UNC Lineberger Comprehensive Cancer Center Institute for Stem Cell Biology and Regenerative Medicine

About

Stephen B. Willingham is an author at Stanford University specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	2.6K
2	Cell Biology	7	7	2K
3	Natural Sciences	2	2	506
4	Engineering	1	1	261
5	Biochemistry	1	1	82

Stephen B. Willingham

Publications

8.8K

Citations

H-Index

Page 1

	Year	Citations
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors Stephen B. Willingham, Jens-Peter Volkmer, Andrew J. Gentles, Proceedings of the National Academy of Sciences	2012	1.6K
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 Mark P. Chao, Siddhartha Jaiswal, Rachel Weissman-Tsukamoto, Science Translational Medicine	2010	750
Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP3 Hanfen Li, Stephen B. Willingham, Jenny P.‐Y. Ting, The Journal of Immunology	2008	646
Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response Diane Tseng, Jens-Peter Volkmer, Stephen B. Willingham, Proceedings of the National Academy of Sciences	2013	629
Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling Joseph A. Duncan, Dan T. Bergstralh, Yanhong Wang, Proceedings of the National Academy of Sciences Innate Immune SystemImmunologyCell DeathImmunologic MechanismCellular Physiology	2007	480
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential Jie Liu, Lijuan Wang, Feifei Zhao, PLoS ONE	2015	460
Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein Stephen B. Willingham, Tiago F. Outeiro, Michael J. DeVit, Science MitophagyGeneticsCell DeathMolecular BiologyMolecular Genetics	2003	424
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors Sharareh Gholamin, Siddhartha S. Mitra, Abdullah H. Feroze, Science Translational Medicine	2017	413
NLRP3 (NALP3, Cryopyrin) Facilitates In Vivo Caspase-1 Activation, Necrosis, and HMGB1 Release via Inflammasome-Dependent and -Independent Pathways Stephen B. Willingham, Irving C. Allen, Dan T. Bergstralh, The Journal of Immunology	2009	346
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Lawrence Fong, Andrew Hotson, John D. Powderly, Cancer Discovery	2019	321

Page 1